Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

Presentation TCT 2019

LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

Presenter: Kenneth Ouriel

September 28, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

Shelley Wood

September 28, 2019

Presentation TCT 2019

Long-Term Safety of Drug-Coated Devices for Femoropopliteal Artery Revascularization: Updated Analysis of Medicare Beneficiary Data

Presenter: Eric Secemsky

September 27, 2019

Presentation TCT 2019

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Presenter: Rebecca Ward

September 26, 2019

Presentation TCT 2019

Potential Study Designs to Address the Mortality Safety Signal

Presenter: Laura Mauri

September 26, 2019

Presentation TCT 2019

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Presenter: Sahil Parikh

September 26, 2019

Presentation TCT 2019

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Presenter: Ian Meredith AM

September 26, 2019

Presentation TCT 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presenter: Elazer Edelman

September 26, 2019

Presentation TCT 2019

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Presenter: Krishna Rocha-Singh

September 26, 2019

Presentation TCT 2019

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Presenter: Konstantinos Katsanos

September 26, 2019

Presentation TCT 2019

1-Year Late Lumen Loss With a Polymer-Coated Paclitaxel-Eluting Stent and a Polymer-Free Paclitaxel-Coated Stent for Femoropopliteal Disease: Study Results

Presenter: Daizo Kawasaki

September 26, 2019

Presentation TCT 2019

New Crossing Techniques for Complex Femoropopliteal Disease

Presenter: Makoto Utsunomiya

September 26, 2019

Presentation TCT 2019

Mortality Risk Following Application of Paclitaxel-Coated Devices in Femoropopliteal Lesion: Results From the CAROOT Study

Presenter: Yoshimitsu Soga

September 26, 2019

Presentation TCT 2019

TCT 63: Jetstream Atherectomy for the Treatment of In-stent Restenosis of the Femoropopliteal Artery: Preliminary Results of the JET-ISR Study

Presenter: Nicolas Shammas

September 25, 2019

Presentation TCT 2019

TCT 62: A polymer-free paclitaxel eluting stent (Zilver® PTX®) versus a bare metal stent (Misago®) for de novo femoropopliteal lesions (BATTLE): a randomised trial

Presenter: Yann Gouëffic

September 25, 2019

Presentation TCT 2019

Can Baseline IVUS Predict Dissection Patterns of Femoropopliteal Lesions?

Presenter: Daizo Kawasaki

September 25, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Kenneth Ouriel About LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

September 26, 2019

Advertisement

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

Long-Term Safety of Drug-Coated Devices for Femoropopliteal Artery Revascularization: Updated Analysis of Medicare Beneficiary Data

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Potential Study Designs to Address the Mortality Safety Signal

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

1-Year Late Lumen Loss With a Polymer-Coated Paclitaxel-Eluting Stent and a Polymer-Free Paclitaxel-Coated Stent for Femoropopliteal Disease: Study Results

New Crossing Techniques for Complex Femoropopliteal Disease

Mortality Risk Following Application of Paclitaxel-Coated Devices in Femoropopliteal Lesion: Results From the CAROOT Study

TCT 63: Jetstream Atherectomy for the Treatment of In-stent Restenosis of the Femoropopliteal Artery: Preliminary Results of the JET-ISR Study

TCT 62: A polymer-free paclitaxel eluting stent (Zilver® PTX®) versus a bare metal stent (Misago®) for de novo femoropopliteal lesions (BATTLE): a randomised trial

Can Baseline IVUS Predict Dissection Patterns of Femoropopliteal Lesions?

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Dr. C. Michael Gibson Talks With Dr. Kenneth Ouriel About LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content